MARKETSPERPSLIVE112
Cash
Portfolio
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive112AccountSocial
Product
Perpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
  1. Medicine

Will the FDA approve retatrutide?

Series Image
  1. Medicine

Will the FDA approve retatrutide?



Chance

Before Jul 1, 2027

45%

Before Jul 1, 2027

45%


Before Jan 1, 2028

85%

▼ 6
Before Jan 1, 2028

85%

▼ 6

Before Jul 1, 2028

87%

Before Jul 1, 2028

87%


2 more

Before Jan 1, 2027

Odds
0% chance
Max payoutJan 1, 2027

$0

$33,004 vol
1D
1W
1M
ALL